Fennec Pharmaceuticals is projected to report Q2 2026 revenue of approximately $16.21 million and an EPS of $0.02, while the stock trades at $11.57 against a $16.00 average analyst target. Investors are primarily focused on the commercial ramp and adoption rate of PEDMARK, specifically its penetration into the Adolescent and Young Adult (AYA) patient population.
Recent performance has been robust, highlighted by a 73% year-over-year revenue increase in Q1 and a significant expansion of the prescriber base to over 5,000 targets. Key operational drivers for the quarter include the efficiency of the Fennec HEARS hub, which has recently achieved an 80% patient conversion rate.